ICI-VPH: Impact of HPV Immunisation Schedules Against HPV — ICI-VPH

Human Papillomavirus Infections Clinical Trial

Official title:
ICI-VPH: Impact Des Calendriers d'Immunisation Contre Les HPV

Status Completed

Clinical Trial Summary

This randomised clinical trial aims to determine whether an immunization schedule comprising two doses of Gardasil administered six months apart is non-inferior to a schedule comprising three doses administered at 0, 6 and 60 months for the prevention of HPV-16 and HPV-18 infections that persist for at least six months, up to ten years after the initial vaccination. The study hypothesis is that the two-dose schedule would offer similar protection as that of a three-dose schedule against persistent HPV-16/18 infections.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02009800
Study type	Interventional
Source	CHU de Quebec-Universite Laval
Contact
Status	Completed
Phase	Phase 3
Start date	November 2013
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03610581` - Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix	Phase 1/Phase 2
Completed	`NCT01077856` - GARDASIL™ Vaccine Impact in Population Study (V501-033)
Completed	`NCT01717443` - Genital HPV Infections Before and After Renal Transplantation	N/A